MAN2B2

Across TCGA pan-cancer cohorts, MAN2B2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MAN2B2 data layer compared with 23 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MAN2B2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MAN2B2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where MAN2B2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	IV	1.000	0.451	.016	10	view →
PDAC	DFS	Quartile	III,IV	0.748	0.261	.026	7	view →
LUAD	DFS	Tertile	III,IV	0.478	0.922	.038	6	view →
UCEC	OS	Tertile	III,IV	0.305	0.807	.022	4	view →
LSCC	DFS	Tertile	II,III,IV	0.563	1.000	.040	2	view →
HNSC	DFS	Quartile	All	0.907	1.000	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MAN2B2–CCRCC (OS)

Open the CCRCC breakdown →